- Record: found
- Abstract: not found
- Article: not found
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M. Forde
1 ,
Jonathan Spicer
1 ,
Shun Lu
1 ,
Mariano Provencio
1 ,
Tetsuya Mitsudomi
1 ,
Mark M. Awad
1 ,
Enriqueta Felip
1 ,
Stephen R. Broderick
1 ,
Julie R. Brahmer
1 ,
Scott J. Swanson
1 ,
Keith Kerr
1 ,
Changli Wang
1 ,
Tudor-Eliade Ciuleanu
1 ,
Gene B. Saylors
1 ,
Fumihiro Tanaka
1 ,
Hiroyuki Ito
1 ,
Ke-Neng Chen
1 ,
Moishe Liberman
1 ,
Everett E. Vokes
1 ,
Janis M. Taube
1 ,
Cecile Dorange
1 ,
Junliang Cai
1 ,
Joseph Fiore
1 ,
Anthony Jarkowski
1 ,
David Balli
1 ,
Mark Sausen
1 ,
Dimple Pandya
1 ,
Christophe Y. Calvet
1 ,
Nicolas Girard
1
April 11 2022
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for
resectable non-small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based
neoadjuvant regimens have shown promising clinical activity; however, data from phase
3 trials are needed to confirm these findings.